Compare BTA & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTA | FATE |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4M | 131.5M |
| IPO Year | N/A | 2013 |
| Metric | BTA | FATE |
|---|---|---|
| Price | $9.48 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 21.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.59 | $0.66 |
| 52 Week High | $10.62 | $2.22 |
| Indicator | BTA | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 51.24 |
| Support Level | $9.25 | $1.03 |
| Resistance Level | $9.55 | $1.17 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 71.87 | 76.81 |
Blackrock Long-term Municipal AdtgTrust is a diversified closed-end investment trust. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The fund, under normal market conditions, invests a majority of its managed assets in municipal obligations and derivative instruments with exposure to such municipal obligations, in each case that are expected to pay interest or income that is exempt from U.S. federal income tax. Its investment portfolio comprises dollar-weighted, long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund's investments have exposure to various sectors such as Corporate, Health, County/City/Special District/School District, Transportation, Education, Utilities, State, Tobacco, etc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.